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Abstract 
Intracellular signalling mediated by secreted Wnt proteins is essential for the establishment of cell fates and 
proper tissue patterning during embryo development and for the regulation of tissue homeostasis and stem 
cell function in adult tissues. Aberrant activation of Wnt signalling pathways has been directly linked to the 
genesis of different tumours. Here, the components and molecular mechanisms implicated in the transduction 
of Wnt signal, along with important results supporting a central role for this signalling pathway in stem cell 
function regulation and carcinogenesis will be briefly reviewed. 
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Introduction 
Wnt proteins, initially identified as the products of the Drosophila Wingless (Wg)and mouse 
Int1 genes, are secreted cysteine-rich glycosylated proteins playing essential roles during embryo 
development and in the maintenance of adult tissue homeostasis [1–6] (for a comprehensive 
overview, the reader is referred to the Wnt gene homepage:  
http://www.stanford.edu/~rnusse/wntwindow.html). During embryo development, Wnt signalling 
has a key role in controlling the pattern of body axis formation as well as in the development and 
maturation of the cardiovascular and central nervous systems and the limbs [1-6]. At this stage of 
development, altered Wnt signalling leads to abnormal morphogenesis and congenital defects [1-
6]. Dysfunction of the Wnt pathway can also result in neurodegenerative disorders and heart 
failure [1-6]. 
 
In adult tissues, Wnt signalling is essential for the regulation of the self-renewal, proliferation 
and differentiation of pluripotent stem cells [1-6]. Wnt signalling is also involved in the regulation 
of cell proliferation, differentiation and survival in several differentiated somatic cell types and in 
cancer cells [1-6]. Consistent with these observations, different components of the Wnt signalling 
pathway have been linked to tumorigenesis, including adenomatous polyposis, colon carcinoma, 
medulloblastoma, tuberous sclerosis and lung cancer. 
  
Wnt proteins and Wnt receptors 
Wnt genes have been identified in a large number of organ-isms, from hydra to human, 
encompassing a wide protein family of paracrine growth factors [1]. Similarly, more than eighty 
target genes of Wnt signalling have been identified in different species from mammalian human 
and mouse, to zebrafish, Xenopus and Drosophila[1]. In humans, at least 19 of the 24 potential 
gene sequences encoding known WNT proteins, as well as their precise chromosome locations, 
have been accurately identified, many of them located in very close positions in the genome (see 
Table 1) [1].  
Table 1. Chromosomal location of WNT genes in humans 
Gene Location 
  
WNT1  12q13 
WNT2  7q31 
WNT2b/13  1p13 
WNT3  17q21 
WNT3a  1q42.13 
WNT4  1p35 
WNT5a  3p14-p21 
WNT5b  12p13.3 
WNT6  2q35 
WNT7a  3p25 
WNT7b  22q13.3 
WNT8a/d  5q31 
WNT8b  10q24 
WNT10a  2q35 
WNT10b/12  12q13.1 
WNT11  11q13.5 
WNT14  1q42 
WNT15  17q21 
WNT16 7q31 
  
 
Wnt genes have been identified in vertebrates and in-vertebrates, but not in plants, unicellular 
eukaryotes such as Saccharomyces cerevisiae or prokaryotes [1]. In vertebrates, Wnt orthologues 
in different species are highly similar in sequence [1]. For example, human and mouse, 
Wnt1orthologues are 98% identical, and human and Xenopus wnt5aare 84% identical at the 
amino-acid level. Phylogenetic analyses of vertebrate and invertebrate Wnts demonstrate 
significant orthologous homology between several human and Drosophila Wnt genes [1]. 
However, the evolutionary relationship between the five Caenorhabditis elegans Wnt genes and 
human WNT genes is less apparent [1]. 
 
Human WNT proteins (Fig. 1) are lipid-modified secreted glycoproteins of very similar size, 
typically containing 350–400 amino acids, and ranging in molecular weight from 39 kDa 
(WNT7A) to 46 kDa (WNT10a) [3]. Little is known about the structure of Wnt proteins, as they 
are notoriously insoluble, but it is well established that all of them have 23 or 24 cysteine residues 
and several highly conserved asparagine-linked glycosylation sites [7, 8], suggesting that Wnt 
protein folding may depend on the formation of multiple intramolecular disulphide bonds. 
Analysis of the signalling activities of chimeric Wnt proteins has shown that the carboxy-terminal 
region of Wnt proteins may play a role in determining the specificity of responses to different 
Wnts [9]. 
  
 
 
 
Fig. 1. Schematic representation of the Wnt protein 
showing the approximate positions of cysteine 
residues. The palmitoylation of wild type Wnt 
occurs through a thioesther to a cysteine 
As a general rule, Wnt proteins are secreted paracrine factors that can act in a cell non-
autonomous manner. Once secreted, Wnt proteins can associate to glycosaminoglycans in the 
extracellular matrix and tightly bind the cell surface [10, 11]. Although tightly bound to the plasma 
membrane, it has been reported that active Wnt factors are also found in the conditioned medium 
of cultured cells [11]. Apart from these scant observations, the precise localization of Wnt proteins 
in vertebrates is poorly understood 
 
Analysis of the localization of Wg in Drosophila, how-ever, has provided critical insights into 
the subcellular distribution of Wnt proteins and the importance of this distribution for signalling 
activity. In the embryonic epidermis, Wg is localized either in intercellular regions that are 
associated with the plasma membrane in producing paracrine cells or in multi-vesicular bodies 
inside Wg-receptor cells, suggesting that Wg is transmitted and received through the endocytic 
pathway [12]. This idea is supported by examination of shibire embryos harbouring a mutation in 
dynamin, a critical component of the endocytic machinery. Dynaminmutants show defects in Wg 
distribution and Wg signalling activity is compromised. Similarly, expression of a dominant-
negative form of shibire also reduces Wg activity [13, 14].  
 
Endocytosis may also contribute to limit the distribution of Wg signal in Drosophila. Thus, in 
developing tissues, cells positioned in an anterior location respective to the Wg source showed 
significantly lower levels of Wg in endocytic vesicles than cells located posterior to Wg-producing 
cells. The asymmetric distribution of Wg closely mimics the activity of the secreted factor, 
exhibiting the strongest short range signalling effect in the posterior as compared to the anterior 
direction with respect to Wg-producing cells. Such critical differences in Wg distribution are the 
result of a rapid degradation of the endocytosed Wg in posterior cells regulated by the epidermal 
growth factor receptor (EGFR) [15]. 
Association of Wg with specific membrane microdo-mains also plays a role in controlling the 
distribution of Wg signals during Drosophila development. In imaginal discs, Wg is found in 
specialised membrane vesicles called argosomes, which are thought to be derived from lipid raft 
microdomains [16]. Incorporation of Wg into argosomes requires heparin sulphate proteoglycans, 
suggesting that proteoglycans play a role in sorting Wg to specialised membrane microdomains in 
Wg-producing cells or, alter-natively, may play a role localising Wg in distinct endocytic 
compartments in receiving cells. 
  
Polarised distribution of Wg transcripts in embryonic epithelial cells is also required for 
optimal signalling activity. High-resolution in situ hybridisation analyses demonstrate that Wg 
transcripts are localised apically in the embryonic epidermis and that this distribution is mediated 
by two cis-acting elements found in the 3 ́ UTR of the Wg mRNA [17]. Mutation of these 
elements results in uniform localisation of Wg transcripts and impaired Wg protein distribution 
and signalling. The asymmetric distribution of Wg transcripts is dependent on dynein-mediated 
microtubule transport [18]. 
 
Wnt proteins are usually divided into functional classes based on their ability to stimulate 
secondary body axis formation in Xenopus embryos and to activate specific signalling cascades 
through the Dishevelled (DVL) factor, a multifunctional phosphoprotein acts as a central 
transducer of the Wnt signal at the plasma membrane as well as in the cytoplasm or cell nucleus 
[19, 20, 21]. Different Wnt proteins use different molecular pathways to activate specific gene 
transcription 
 
The canonical Wnt pathway (see below) use β-catenin (Ctnnb1) as the central component and 
involves Wnt1, Wn-t3a and Wnt8. Members of the Wnt1 class are stimulators of a secondary body 
axis in Xenopusand include Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8 and Wnt8a. Wnt proteins of this 
class bind to the Fzd transmembrane receptor and to the lipoprotein-related protein 5/6 (Lrp5/6) 
co-receptor.  
 
There are two other known pathways used by Wnt proteins to activate gene transcription (see 
below). The non-canonical Wnt/Ca
2+
 pathway uses intracellular calcium (Ca
2+
) release as a central 
component and involves Wnt4, Wnt5a and Wnt11 [22]. The Wnt5a class cannot induce secondary 
axis formation in Xenopus and includes the Wnt proteins of Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a 
and Wnt11. In the planar cell polarity (PCP) pathway, Wnt proteins bind the Fzd transmembrane 
receptor and use Dvl to activate effector pathways through Rho and Rac small GTPases and Jun 
N-terminal kinase (Jnk) [23]. In the Wnt-Ca
2+
-dependent pathways, calcium-dependent kinases are 
activated through G-protein signalling that leads to a rise in intracellular Ca
2+
 either through 
cGMP or phospholipase activation [24, 25]. 
 
In mammals, receptors of Wnt proteins encompass at least ten isoforms of the Fzd protein 
family. The Fzd proteins are named after the fi rst member of the Drosophila tissue polarity gene 
Frizzled (Fzd). Members of the Fzd protein family are considered as a distinct family of G-protein-
coupled receptors [26]. Interestingly, Fzd proteins can bind proteins from other protein families, 
such as Spondin and Norrin, and the Fzd CRD also exists in several other proteins that include the 
soluble secreted Fzd-related proteins (Sfrp) [27], some receptors of tyrosine kinases [28], 
carboxypeptidase Z [29] and an isoform of collagen [30]. These proteins can act as important 
regulators of Wnt-Fzd signalling. 
 
In addition to the Fzd protein receptors, other obligate co-receptors also are necessary for 
canonical Wnt signalling. The best known are the low-density-lipoprotein receptor 5/6 family 
(Lrp5/6) [31]. In the canonical Wnt-Fzd pathway, Wnt binds to both the Fzd receptor and Lrp5/6 
[31], resulting in the inhibition of the downstream component glycogen synthase kinase-
3β(Gsk3β). Wnt signalling can also be transmitted through the binding of extracellular domain of 
Lrp5/6 to Axin, a key component in the Gsk3βcomplex, indicating that the Lrp5/6 receptor is an 
important part of the Wnt-Fzd signalling pathway [32, 33]. 
 
Ryk represents another co-receptor of Wnt signalling belonging to one of the divergent 
members of the receptor tyrosine kinase family. Ryk can form a complex with Fzd proteins 
inducing the activation of the canonical Wnt signalling pathway, and regulate the non-canonical 
Wnt signalling through Fzd-independent pathways [34, 35].  
  
Wnt protein secretion, extracellular transportand reception 
Different proteins involved in Wnt protein processing and secretion from producing paracrine 
cells have been identified, including the porcupine acyl-transferase, the multi-pass transmembrane 
protein wntless/eviand the Retromer complex [2] (Fig. 2). These proteins are involved in the 
palmitoylation of Wnt proteins in the endoplasmatic reticulim (porcupine) and in the transport of 
palmytoilated Wnt proteins to secretory vesicles, formation of lipid particles and subsequent 
secretion (wntless/eviand the Retromer complex). Genetic screens have identified the multipass 
transmembrane protein wntless (wls)/evenness interrupted (evi) as a key component of the Wnt 
secretory pathway [36]. In Drosophila and mammalian tissue culture, RNAi knock-down of 
wls/evi/mom-3 in cells overexpressing Wnt inhibits a Wnt-responsive luciferase reporter in co-
cultured responding cells, showing that wls/evi acts in a cell non-autonomous manner [37]. 
Wls/evi deficiency inhibits Wnt transport to the surface of cells [38]. These phenotypes are similar 
to those observed in porcupine mutants. In contrast to the function of Porcupine, however, the 
secretory activity mediated by wls/evi does not depend on the palmitoylation status of Wnt 
proteins: the secretion of Wnt proteins in which the palmitoylation site is mutated is still impaired 
in wls/evimutants. 
 
Recently, large molecules required for lipid transport called lipoprotein particles have been 
implicated in the transport of Wnt proteins and other lipid-modified proteins such as Hedgehogs 
[2] (Fig. 2). While previously postulated to be exosome-like particles, these structures, termed 
argosomes, are now thought to be exogenously derived lipoproteins. A model is proposed where 
palmitoylated proteins associate with lipoprotein particles on the extracellular face of cells. Traffic 
of Wnt proteins from one cell to the next requires this association, as RNAi knock-down of 
lipophorin, a Drosophilalipo protein, narrows the range of Wg signalling in the wing disc. It will 
be interesting to see what mechanism underlies these lipoprotein particles’ aiding in Wnt transport 
and whether this mechanism of Wnt transport is conserved across all species. In addition, 
transcytosis may regulate Wnt movement. In yeast, proteins of the retromer complex direct 
endosomal-Golgi retrieval of proteins. In vertebrate systems, the retromer complex func-tions in 
basal-to-apical transcytosis [39]. In C. elegans, the orthologue of the yeast retromer complex 
subunit Vps35p is required for the long-range signalling capabilities of Egl20 (C. elegansWnt 
orthologue) [40]. It has been pro-posed that the retromer complex promotes the association of 
secreted Wnts with other proteins required for ligand transport, such as lipoprotein particles (Fig. 
2). 
 
The seven-pass transmembrane Fzd protein was the first receptor found to transduce a Wnt 
signal (Fig. 3). Fzd proteins contain a large extracellular domain containing a conserved motif 
comprised of 10 cysteine residues called the cysteine-rich domain (CRD). The CRD domains from 
different Fzd receptors can bind to multiple Wnt proteins with high affinity [41]. At the 
cytoplasmic side, Fzd receptors may directly interact with the Dishevelled (DVL1) protein, a 
central transducer of Wnt signalling (Fig. 3). 
 
The single-pass transmembrane proteins of the low-density lipoprotein (LDL) family called 
Lrp5 and Lrp6 are require to translate Wnt signalling into the cytoplasm of receptor cells [31]. 
Following Wnt binding, Fzds forms a complex with co-receptor LRP proteins that can activate 
intracellular targets. LRP5 and LRP6 proteins have a relatively small intracellular domain and a 
large extracellular domain containing several potential protein interaction domains [42]. Altered 
proteins that lack the extracellular portion but still contain the transmembrane and intracellular 
domains produce a constitutively active canonical Wnt signal. 
 
Interestingly, the Axin protein, a negative regulator of Wnt signalling, can bind to the 
cytoplasmic tail of Lrp6, providing a mechanism by which Axin is released from β-catenin [32]. 
This interaction changes the fate of β-catenin; instead of being destroyed, it is accumulated in the 
cytoplasm inducing Wnt-dependent gene transcription. The binding of Axin to the Lrp6 tail is 
promoted by phos-phorylation of Lrp6 with a central PPPSP motif as a hall-mark. The serine in 
the PPPSP motif is modified by Gsk3b, leading to activation of signalling [43].  
  
 
 
 
Fig. 2. In Wnt-producing cells, the Wnt protein is 
palmitoylated in the endoplasmic reticulum by the 
porcupine acyl-transferase. Further transport and secretion 
of the Wnt protein in secretory vesicles is con-trolled by 
the multi-pass transmembrane protein Wntless/Evi, which 
is present in the Golgi and/or on the plasma membrane. 
The retromer complex may act in the cytoplasm of Wnt-
producing cells to generate Wnt forms that can be 
transported outside the cells in the form of a lipoprotein 
particle 
 
 
 
 
 
 
 
Fig. 3. Wnt proteins can interact with multiple receptors. In 
the canonical Wnt/β-catenin signalling pathway, Wnt 
proteins interact with Frizzled receptors through the CRD 
domain. The LRP5/6class of transmembrane lipoproteins 
act as co-receptors of Frizzled. The RYK/Derailed-type 
receptors have a tyrosine kinase motif and a WIF ligand-
binding domain that can bind Wnt proteins in Frizzeld-
dependent or –independent mechanism. Finally, Wnt scan 
also interact with the Ror tyrosine kinases to mediate a 
signal that can inhibit β-catenin TCF activity in the nucleus 
 
 
There are other proteins with known Wnt-binding do-mains that can serve as receptors for Wnt 
ligands. The single-pass tyrosine kinase Ror2, although structurally distinct from Fzds receptors, is 
involved in Wnt signalling [44, 45]. Ror2 can mediate the Wnt5a signal that is responsible for 
inhibition of β-catenin-TCF signalling [46]. Thus, the CRD domain may enable alternative 
signalling pathways in response to Wnt ligand stimulation. Another well characterised Wnt-
binding domain is the Wnt inhibitory factor (Wif) module, which is also found in the cell surface 
atypical receptor tyrosine kinase RykK. In mammalian systems, Ryk is required for Wnt3a-
mediated canonical Wnt signal-ling [35]. Understanding the ways in which alternative Wnt 
receptors such as Ryk and Ror2 interact with known Wnt signalling components and what 
intracellular signalling cascades they initiate will lead to stimulating advances in this issue. 
Wnt signalling and embryo development  
Wnt proteins are essential for embryogenesis, as demonstrated by the loss-of-function 
experiments in mice models of 9 of the 18 mouse Wnt genes (see Table 2). A full list of Wnt genes 
and their mutant phenotypes in vertebrates and invertebrates can be found at the Wnt gene 
homepage (http://www.stanford.edu/~rnusse/wntwindow.html).  
  
Table 2. Developmental functions of mouse Wnt genes 
Gene Natural allele Phenotype of knockout functions 
   
Wnt1 Swaying  Loss of a portion of midbrain and cerebellum; deficiency in dorsal neural-tube derivatives, 
including neural-crest cells in double knockout with Wnt3a 
Wnt2  Placental defects 
Wnt3  Defects in axis formation and gastrulation; defects in hair growth and structure 
Wnt3a Vestigial tail  Defects in somite and tailbud development; deficiency in dorsal neural-tube derivatives, 
including neural-crest cells in double knockout with Wnt1; loss of hippocampus 
Wnt4  Defects in kidney development; defects in female development; absence of Müllerian duct, 
ectopic synthesis of testosterone in females; defects in mammary gland morphogenesis 
Wnt5a  Truncated limbs, shortened anterior–posterior axis, reduced number of proliferating cells 
Wnt7a Postaxial 
hemimelia  
Defects in limb polarity; female infertility due to failure of Müllerian duct regression; defects 
in uterine patterning; defects in synapse maturation in the cerebellum 
Wnt7b  Placental defects 
Wnt10b  Inhibition of adipogenesis 
   
 
Overexpression and antisense knockdown analyses in Xenopus have demonstrated that the 
Wnt/β-catenin path-way is required for the specification of dorsal cell fates [47]. XenopusFzd7 is 
important for establishing dorsal cell fates, suggesting that Wnt ligand in also important in this 
process [48]. Targeted knockout of Wnt3in mice results in defects in axis formation and 
gastrulation, suggesting a conserved role for Wnts in controlling the establishment of the dorsal-
ventral axis in vertebrates. 
 
In flies, Wnt signalling has several functions during development. The wg gene is necessary 
for cell fate choices in the ventral epidermis during embryogenesis, as well as for many other 
functions, and Drosophila Wnt2 is required for testis and adult muscle development. In C. elegans, 
genetics studies have defined a number of roles of Wnts, including establishment of polarity and 
endodermal cell fates in the early embryo and regulation of cell migration, as an example.  
 
In the mouse intestine, Wnt signalling is the central cell fate determinant along the crypt-villus 
axis [49]. The stem cell niche in the crypt of the intestine is destroyed in neonatal mice lacking the 
transcription factor Tcf4 [50]. In these mice, the differentiated villus epithelium is normal, 
indicating that Wnt signalling is required for the establishment of the intestine niche but not for 
cell differentiation. Transgenic mice over-expressing the Wnt agonist R-spon-din-1 present 
hyperproliferation of intestinal crypts [51], indicating that Wnt is an essential mitogen for crypt 
stem cells.  
 
Wnt signalling is also required for hair follicle development. Mice lacking Lef1present a 
significantly reduced number of hair follicles [52], while transgenic Lef1over-expression promotes 
de novo hair follicle formation [53]. In the same way, transgenic over-expression of a 
metabolically stable form of β-catenin induces the formation of hair follicles [53]. By contrast, 
conditional deletion of β-catenin or transgenic over-expression of a dominant negative form of 
Lef1 aborts the development of hair follicle precursors [54]. These observations implicate that Wnt 
signalling through Lef1is essential to activate the differentiation programme of the hair follicle 
precursor resident in the bulge region of the hair follicle [55]. In the haematopoietic system, 
overexpression of β-catenin or stimulation with purified Wnt proteins promotes the proliferation 
and self-renewal of haematopoietic stem cells in vitro[56]. 
  
The Wnt signalling pathways 
The canonical Wnt pathway 
The canonical Wnt signalling pathway is referred to as the Wnt/β-catenin pathway since it can 
regulate β-catenin protein levels to control the activation of Wnt-responsive target genes (Figs. 4 
and 5). All Wnt signalling pathways are initiated by interaction of Wnt proteins with Fzd 
receptors, but in this pathway the Wnt signalling pathway will only be activated if the binding of 
the Wnt protein to the Fzd receptor takes place in the presence of the co-receptor Lrp5/6 resulting 
in the formation of a Wnt:Fzd:Lrp5/6 tri-molecular complex [31, 32]. Once Wnt protein binds to 
the Fzd receptor and the co-receptor Lrp5/6, this is followed by recruitment of Dvl [57]. The 
formation of the Wnt-Fzd-Lrp5/6 complex also promotes the Lrp5/6-mediated degradation of Axin 
[32]. The inhibition of Gsk3b activity by Wnt with the degradation of Axin blocks the formation 
of the protein complex consisting of Gsk3b, Axin, and adenomatous polyposis coli (Apc) tumour 
suppressor protein. If the formation of the protein complex of Gsk3b, Axin and Apc tumour 
suppressor protein does not occur, accumulation of free β-catenin results in its translocation to the 
nucleus.  
 
 
 
Fig. 4. Schematic representation of the canonical Wnt/β-catenin signalling pathway showing the 
links other processes and pathways through different interactions of individual components 
Once positioned in the nucleus, the free β-catenin acts as a transcription factor and activates 
Tcf and Lef by forming nuclear complexes with members of the Tcf/Lef transcription factor 
family [58]. This leads to the transcription and expression of a variety of Wnt-responsive target 
genes such as Myc, Ccnd1(cyclin D1) and Axin2. In addition, the complexes of Tcf/Lef and β-
catenin may cooperate with factors activated by other signalling pathways to alter cellular 
remodelling processes. The canonical Wnt signalling pathway is also activated by several other 
cellular mechanisms. The shifting of proteins from the cadherin-bound pool to the cytoplasmic 
pool can increase the amount of available free β-catenin for the activation of target genes. Several 
receptor tyrosine kinases can phosphorylate tyrosine residues of the β-catenin and cadherin–
catenin complex to allow β-catenin to become dissociated from the complex and enhance the 
amount of β-catenin in the cyto-plasm for subsequent translocation to the nucleus.  
 
Furthermore, surface receptors, such as EGFR, Mst1r (c-Ron), Erbb2 and erythropoietin 
receptor (Epor) can then stimulate the canonical Wnt signalling pathway [59, 60]. In addition, both 
insulin-like growth factor and erythropoietin (EPO) lead to β-catenin stabilisation [60]. The 
canonical Wnt signalling pathway can also regulate cyclin D1 activ-ity through inhibition of 
GSK3β, Creb (cAMP-responsive-element-binding protein) and PKA (protein kinase A) signalling 
[61, 62].  
 
 
 
Fig. 5. Canonical Wnt signalling pathway. In the absence of secreted Wnt proteins, β-
catenin is rapidly phosphorylated by a complex containing Axin, APC and the GSK3 
and CKI protein kinases. Phosphorylated β-catenin is recognised by the Slimb/β-TrCP 
component of the E3 ubiquitin ligase, ubiquitinated, and targeted for destruction by the 
proteasome. In the presence of the Wnt signal, the destruction complex is disorganised 
by recruitment of Axin to the cell membrane by Dsh. Metabolically stable β-catenin can 
accumulate in the cytoplasm and translocate to the nucleus to interact with members of 
the Lef/Tcf family of transcription factors and activate gene transcription 
The Wnt/calcium pathway 
Wnt-induced release of intracellular calcium is sufficient to activate different intracellular 
calcium-sensitive enzymes such as protein kinase C, Prkc [63, 64], calcium-calmodu-lin-
dependent kinase II, Camk2 [65, 66] and the calcium-sensitive phosphatase calcineurin (Ppp3C) 
that subsequently can activate the transcription factor Nfat (Fig. 6) [67]. Calcium signalling is a 
rapid event upon receptor stimulation.  
 
Purified Wnt5a or Wnt5a-derived peptides are able to trigger calcium release in several cell 
types [24, 66, 68]. The release of intracellular calcium is a rapid response of a cell within seconds 
upon ligand binding and depends on heterotrimeric G-proteins [24] and the activation of the 
phosphatidyl inositol cycle. Through the regulation of Pde6, a cGMP-specific phosphodiesterase, 
this pathway is also linked to the regulation of protein kinase G in some cell types [24]. The 
Wnt/calcium pathway has been linked to the activation of nemo-like kinase (Nlk), which is able to 
phosphorylate Tcf transcription factors and consequently inhibits canonical Wnt signalling. This 
pathway is involved in dorsoventral patterning of early Xenopusand zebrafish embryos [69], 
regulation of the Wnt/β-catenin pathway [70], tumour formation [66] and more recently the 
regulation of epithelial-mesenchymal transitions [71]. 
  
 
 
 
Fig. 6. Canonical versus non-canonical Wnt signalling pathways. 
Binding of different Wnt proteins to different receptor complexes can 
result in the specific activation of either the canonical Wnt pathway or 
a non-canonical Wnt pathway (the Ca2+-dependent or the PCP 
pathway) resulting in the selective activation of a specific set of target 
genes 
The Wnt/JNK or PCP pathway 
This pathway forms the third signalling pathway activated by Wnts. This pathway was 
described earlier in D. melano-gaster as the PCP pathway. This pathway regulates the polarity of 
epithelial cells within the plane of the epithelium. In vertebrates, a similar pathway has been 
described regulating convergent extension movements during gastrulation or neurulation and cell 
migration of neural crest cells [72, 73]. On the other hand a distinct Wnt (Wingless) ligand has not 
been assigned to this pathway in Drosophila; in vertebrates Wnt11 or Wnt5a is able to activate this 
signalling cascade. The core element of the Wnt/JNK pathway (Fig. 6) includes the activation of 
Rho GTPases and related proteins such as RhoA, Akt1 (Rac) or Cdc42 downstream of Dvl1l1 
(DSH). The GTPases can activate more down-stream mediators like Jnk or Rho kinase.  
 
In PCP signalling, this cascade of events is complemented by transmembrane proteins such as 
strabismus (Stbm, official name Vang), diego (dgo) or prickle (pk) that also can bind dishevelled 
[74, 75]. It is thought that the asymmetric distribution of proteins such as stbm and pk within 
epithelial cells is involved in setting up planar polar-ity [75]. In vertebrates, the receptor tyrosine 
kinase ROR2 has been shown to regulate convergent extension movements and bind to Wnt 
protein [76]. Ror2 was found to be upstream of Cdc42 and to regulate JNK activity [45]. 
  
G-proteins in Wnt signaling 
Recent findings indicate the involvement of G-proteins in canonical signalling as well as PCP-
type signalling. Activation of Fzd1 signalling through inducible Fzd receptors in F9 
theratocarcinoma cells required the function of Gαq and Gαo, whereas triggering Fzd2 signalling 
through the corresponding inducible Fzd receptor requires Gαo and Gαt. Further evidence was 
provided by the observation that overexpression of Rgs4, a regulator of G-protein signalling, in 
early Xenopusembryos interferes with Wnt8-induced secondary axis formation [77]. Tcf/β-
catenin-mediated reporter gene activity as well as endogenous Wnt/β-catenin target genes can be 
induced by constitutively active Gαo and Gαq subunits [78]. Depletion of G-proteins by the use of 
antisense oligonucleotides or siRNA interferes with Wnt- and Fzd-induced activation of the 
Wnt/β-catenin pathway [78]. In Drosophila, genetic epistasis experiments are indicative of the 
involvement of G-proteins downstream of Fzd but upstream of Dvl in both canonical and non-
canonical Wnt signalling [79]. 
 
The list of G-protein subunits involved in Wnt signal-ling becomes even longer if one 
considers the finding that some Wnts probably activate protein kinase A through the classical Gαs 
pathway [61] whereas a non-canonical Wnt ligand-like Wnt11 reduces Prka activity through Gαi 
[80]. PRKA has been correlated to the regulation of β-catenin stability as well as JNK activity 
[80]. Taking into account the fact that the Wnt/calcium pathway also involves G-proteins as 
outlined above, it seems very probable that all three Wnt signalling branches involve 
heterotrimeric G-proteins. Considering Wnt signalling to be G-protein coupled indeed leaves us 
with a plethora of different Wnt/Fzd/G-protein and co-receptor combinations for potential 
downstream effects. 
Secreted antagonists of the Wnt signalling pathway 
Secreted frizzled related proteins (Sfrp) are multifunctional modulators of Wnt and bone 
morphogenetic protein (Bmp) signalling that are required for the development of most organs and 
the homeostasis of different adult tissues [2]. Sfrp fold in two independent domains: the cysteine-
rich domain (Sfrp-CRD) related to the extracellular portion of Fzd and the Netrin module (Sfrp-
NTR) defined by homologies with molecules such as Netrin 1, inhibitors of metalloproteases and 
complement proteins. Due to its structural relationship with Fzd, it is believed that Sfrp-CRD 
interferes with Wnt signalling by binding and sequestering the ligand. In contrast, the functional 
relevance of the SFRP-NTR has been barely addressed [2].  
 
The Sfrp-CRD contains ten cysteines with a pattern of five disulphide bridges identical to that 
of the extracellular CRD of Fzd [81, 82]. Due to this structural relationship, it is generally assumed 
that SFRP-mediated Wnt signalling inhibition results from the interaction between the ligand and 
Sfrp-CRD, which has been actually shown to immuno-precipitate with Wnt1 and Wnt2 [83, 84]. 
However, Sfrp-CRD can also form homo- and heterodimers with the CRD domain of Fzd 
receptors [83], suggesting potential alternative mechanisms of action. 
 
Sfrp of different subgroups have different biochemical interactions with Wnt ligands. In 
support of this assumption, plasmon resonance binding studies using Sfrp1, 2, 3, 4 and Wnt3a and 
Wnt5 have shown that Wnt5 binds preferentially to Sfrp1 and 2, while Wnt3a binds at least two 
sites in Sfrp1, 2, 4 and one in Sfrp3 [85]. Sfrp molecules interact with both Wnt and Fzd in 
multiple ways and these interactions can modulate signal transduction in either a positive or 
negative manner. There are several possible mechanisms by which Sfrp can modulate Wnt 
signalling (Fig. 7). SFRP could sequester Wnt ligands through the NTR domain, thus acting as 
antagonists (Fig. 7a) or act in a dominant-negative manner through the formation of inactive 
complexes with Fzd receptors, preventing signal activation (Fig. 7b). Alter-natively, SfrpP could 
favour Wnt–Fzd interaction by simultaneously binding to both molecules and, thus, synergising 
with signal activation (Fig. 7c). Finally, in the absence of Wnt ligands, Sfrp-CRD: Fzd-CRD 
heterodimer formation could trigger signal transduction (Fig. 7d). Notably, the activation of the 
Fzd receptors by a proposed ligand-antagonist is not unique to Sfrp1, as Dkk2, which belongs to a 
different family of Wnt antagonists, can activate Wnt canonical signalling cooperating with at least 
three different Fzd [86]. 
 
 
 
Fig. 7. SFRP mode of action may rely on multiple interactions with Wnt ligands and/or 
Frizzled receptors. Possible mechanisms by which SFRPs could modulate Wnt/Frizzled 
signalling: (a) SFRP scan antagonise Wnt activity by directly binding to the ligand 
through its Netrin-related domain. (b) SFRPs could interact directly with Frizzled 
receptors through their corresponding CRD motifs and prevent signal transduction. (c) 
Frizzled, Wnt and SFRP molecules could form heterotrimeric complexes, where SFRP 
could present the Wnt ligand to the Frizzled receptor thanks to the differential 
interactions of the CRD and NTR domains. (d) In the absence of Wnt ligands, SFRPs 
can directly bind a Frizzled receptor and transduce a signal  
Genetic manipulations selectively eliminating one or the other domain of Sfrp may provide 
further insights. Additional studies characterising the functionally relevant interactions among 
Sfrp-NTR:Wnt or Sfrp-CRD:Fzd pairs are also undoubtedly needed. Interaction with additional 
components of the Wnt signalling cascade also needs to be addressed. Particularly relevant might 
be the contributions of proteoglycans, which are known to bind Wnts [87] and may additionally 
interact with the Sfrp-Ntr.  
  
Alternative extracellular mechanisms to inhibit Wnt signalling involve Dkk proteins that are 
secreted regulators which can bind to the co-receptor Lrp5/6 preventing the formation of the 
Lrp:Fzd:Wnt complex and thus inhibiting the induction of Wnt signalling. Furthermore, in the 
presence of Kremen1 and 2, two-transmembrane proteins Dkk and Lrp5/6 can form a tertiary 
complex and to be internalised, reducing the availability of Lrp5/6 receptor for its ligands. 
 
Recently, the two members of a gene family (Sost, encoding sclerostin, and Wise) have been 
added to this list of extracellular Wnt antagonists. They are capable of binding to Lrp5/6 and, in 
this way, modulating Wnt signaling. 
 
In the cytosol as well as in the nucleus additional mechanisms are available for regulating the 
canonical Wnt signalling pathway. The former involves regulation at the level of any of the 
components of the tertiary Gsk3b:Axin:Apc complex that leads to phosphorylation and 
subsequently degradation of β-catenin. Finally the nuclear availability of transcription factors Tcf, 
Lef and cofactors can influence the signalling. 
Wnt signalling and tissue homeostasis 
Wnt signalling in the epithelium 
The Wnt cascade is essential in establishing cell fate along the crypt-villus axis of the intestinal 
epithelium. β-Catenin is the major cytoplasmic signal transducer of the canonical Wnt pathway. 
Accumulation of nuclear β-catenin, the hall-mark of active Wnt signalling, is evident in the crypt 
cells of the normal intestine, whereas differentiated villus cells present β-catenin at their 
basolateral membrane, where it is important to ensure cell adhesion. Deletion of the transcription 
factor Tcf4, the most prominent effector of Wnt signalling in the gastrointestinal tract, produces a 
severe intestinal phenotype accompanied by neonatal lethality.  
 
While the villous epithelial compartment is practically unaffected in these mice, intestinal 
crypts are completely absent and no proliferating cells are observed, indicating that Wnt signals 
are required for the maintenance of the crypt proliferative compartment (Fig. 8). In agreement with 
these fi ndings, inhibition of the Wnt receptor by expression of the secreted antagonist Dkk1 in 
adult mice leads to a complete loss of crypts. Thus, in physiological conditions, the β-catenin:Tcf4 
complex drives the transcription of a set of target genes that determine the characteristics of the in-
testinal crypt cells. Wnt signals are turned off in differentiated cells present in the villi, hence 
establishing the crypt–villus boundary. The only terminally differentiated cells in the intestine that 
present nuclear β-catenin and active Wnt signalling are the Paneth cells (Fig. 8) and this specific 
fea-ture might account for their downward migration towards the bottom of the crypts, contrary to 
all the other differenti-ated cell types of the gut. 
 
The same genetic programme that is physiologically active in crypt progenitor cells can also 
promote colon carcinogenesis. Indeed, loss of the tumour suppressor APC (adenomatous polyposis 
coli), a key negative regulator of Wnt signals that functions by controlling β-catenin degradation, 
is the signature of the vast majority of human intestinal tumours [88], both in hereditary 
syndromes and in sporadic colorectal cancers. In the rare cases where APC is not inactivated, 
human intestinal tumours usually show activating mutations in β-catenin itself, or loss-of-function 
mutations in Axin2, a protein that cooperates with APC in β-catenin degradation. These data 
underscore the central role of Wnt signalling activation in the transformation of intestinal 
epithelial cells. 
  
 
 
 
Fig. 8. Wnt and Hh signalling are directly implicated in small intestine 
homeostasis. Crypt mesenchymal cells express and secrete Wnt 
ligands that can act as proliferative signals to stimulate the growth and 
differentiation of crypt cells. Similarly, IHh, expressed and secreted 
by epithelial cells of the villus, regulates the activity of the underly-
ing stromal cells expressing the Hh effectors Patched (Ptch) and Gli; 
Ihh also contributes to BMP activation in the mesenchyme 
Wnt signalling in bone formation 
Osteogenesis is stimulated by canonical Wnt signalling in different ways. In early stages the 
differentiation of mesenchymal stem cells to osteoblast precursors is stimulated while alternative 
differentiation of these stem cells towards adipocytes or chondrocytes is inhibited [89]. These 
early steps can be followed in an ex vivo culture system, referred to as micromass cultures, using 
mesenchymal limb bud cells from either chicken or mouse embryos. Using this system it has been 
demonstrated in chickens that a number of Wnt molecules, Wnt1, Wnt3a, Wnt4, Wnt7a, Wnt9a 
(formerly known as Wnt14) and Wnt11, can inhibit chondrogenesis [90]. The underlying 
mechanisms resulting in an inhibition of chondrogenesis might be different for the individual 
ligand; for Wnt9a it was demonstrated that β-catenin is required for its inhibitory effect [91]. The 
Wnt ligands, Wnt9A and Wnt7B, are the likely candidates for regulating osteoblastogenesis, since 
they are expressed in the perichondrium/periosteum and are regulated by Indian Hedgehog (Ihh) 
signalling [92]. 
 
There also exist evidence for an effect of non-canonical Wnt signalling at different stages of 
bone cell metabolism. Non-canonical Wnt signalling was shown to suppress Pparg function 
through Camk2-Map3k7 (Tak1)-Map3k7ip2 (Tab2)-Nlk and induce Runx2 expression. This 
promotes osteoblastogenesis in bone marrow mesenchymal progeni-tors in preference to 
adipogenesis. Osteoblastogenesis is also stimulated by non-canonical Wnt signalling through G-
protein-linked activation of Prkcd providing another osteogenic mechanism. Finally, an anti-
apoptotic effect both on osteoblast progenitors and osteoblasts was shown for Src/Mapk1 (Erk) 
and Pik3 (Pi3k)/Akt signalling, acting synergistically with canonical Wnt signalling. 
  
Target genes of Wnt signaling 
The Wnt signalling pathway plays an important role in embryonic development, cell 
differentiation and cell proliferation [93]. The biological effects of the Wnt pathway are mediated 
via the regulation of direct (primary) and indirect (secondary) target genes (for a list of target 
genes see http://www.stanford.edu/~rnusse/pathways/targets.html) [94, 95].  
 
The transcription activation by Tcf/Lef and β-catenin is a crucial step in the direct target gene 
activation by the pathway. Thus the activation of a Wnt target gene by Tcf via a Tcf/Lef binding 
motif within the promoter region indicates the direct regulation. Direct Wnt target genes are the 
cell cycle kinase activator cyclin D1 and the transcription factors Myc and Etv4 (PEA3) [96]. 
While the regulatory mechanism of direct target genes is well established, there are few data 
available about the regulation of indirect Wnt targets. A prominent indirect negative target is the 
cell cycle kinase inhibitor Cdkn1a (p21/Waf1), which is induced in cells expressing dominant 
negative Tcf [97]. There are indications that p21/Waf1 expression is regulated by the relative 
levels of the Myc interacting zinc finger pro-tein-1 PIAS2 (Miz1) and the direct Wnt target Myc 
[98].In the absence of Myc, Miz1 activates p21/Waf1 expression, while in the presence of high 
Myc levels, Miz1 together with Myc functions as a repressor of p21/Waf1 transcription. In 
epithelial cells of the intestine, the Myc-Miz1-p21/Waf1 cascade acts as a switch between 
differentiation and proliferation [97].  
 
There are several other known genes, which show a de-creased expression level in Wnt-
activated cells. Examples are targets of the Jun (Ap1) family of transcription factors, which show 
decreased expression in Wnt-activated cells [99]. Many microarray screenings have been 
performed aiming to identify new target genes of the Wnt pathway [99, 100]. Until now, only a 
limited number of candidate target genes have been confirmed and further characterised by 
experimental methods: conductin, cyclin D1, En-2, ID2, Mmp7, Myc, Nkd, Siamois, Tcf-1, Twin, 
Ubx, Xbra, Xnr3. 
Wnt signalling and disease 
Metabolic disease 
The Wnt signalling pathway has a signifi cant role in cellular metabolism, especially in 
disorders that involve diabetes mellitus (DM). Type 2 DM represents at least 80% of all diabetics 
and is dramatically increasing in incidence as a result of changes in human behaviour and 
increased body mass index. Type 1 insulin-dependent DM accounts for only 5–10% of all 
diabetics, but is increasing in adolescent minority groups. Yet the incidence of undiagnosed 
diabetes, impaired glucose tolerance and fluctuations in serum glucose in the young raises further 
concerns [101]. Individuals with impaired glucose tolerance have more than twice the risk for the 
development of diabetic complications than individuals with normal glucose tolerance. Regarding 
the vascular and nervous systems, patients with DM can develop severe neurological and vascular 
disease that can lead to an increased risk for cognitive decline. Diseases of the nervous system can 
become the most debilitating com-plications for DM and affect sensitive cognitive regions of the 
brain, such as the hippocampus that modulates memory function, resulting in significant functional 
impairment and dementia. Interestingly, the development of insulin resistance and the 
complications of DM in the nervous and vascular systems can be the result of cellular oxidative 
stress [102]. 
 
In patients with DM, elevated levels of ceruloplasmin are suggestive of increased reactive 
oxygen species and acute glucose fluctuations may promote oxidative stress [103]. 
Hyperglycaemia can lead to increased production of reactive oxygen species in endothelial cells, 
liver and pancreatic β-cells. Prolonged duration of hyperglycaemia is not necessary to lead to 
oxidative stress injury, since even short periods of hyperglycaemia generate reactive oxygen 
species, such as in vascular cells. Recent clinical correlates support these experimental studies to 
show that acute glucose swings in addition to chronic hyperglycaemia can trigger oxidative stress 
mechanisms during type 2 DM, illustrating the importance of therapeutic interventions during 
acute and sustained hyperglycaemic episodes [103]. The preservation of cellular energy reserves is 
dependent upon the maintenance of mitochondrial integrity during DM. For example, chronic 
exposure to elevated levels of free fatty acids can increase reactive oxygen species production in 
cells and has been shown to lead to mitochondrial DNA damage and impaired pancreatic β-cell 
function [104]. Insulin resistance in the elderly also has been associated with elevation in fat 
accumulation and altered mitochondrial oxidative and phosphorylation activity [105]. Current 
studies suggest that abnormalities in the Wnt signalling pathways, such as with transcription factor 
7-like 2 gene (TCF7L2), may impart increased risk for type 2 DM in some populations [106] as 
well as have increased association with obesity [107]. Additional work has described the 
expression of Wnt5b in adipose tissue, the pancreas and the liver in diabetic patients, suggesting a 
potential regulation of adipose cell function. 
 
Clinical observations in patients with coronary artery disease and the combined metabolic 
syndrome with hyper-tension, hyperlipidaemia and DM have observed impaired Wnt signalling 
through a missense mutation in LRP6 [108]. Experimental studies in mice with hyperglycaemia 
through a high-fat diet also demonstrate increased expression of some Wnt family members, such 
as WNT3A and WNT7A. In addition, intact WNT family members may offer glucose tolerance 
and increased insulin sensitivity as well as protect glomerular mesangial cells from elevated 
glucose-induced apoptosis. Animals that overexpressed WNT10Band were placed on a high-fat 
diet had a reduction in body weight, hyperinsulinaemia and triglyceride plasma levels and 
improved glucose homeostasis [109]. These clinical and experimental observations for the Wnt 
pathway in conditions associated with hyperglycaemia and DM suggest a potential protective 
cellular mechanism for WNT. Recent in vitrostudies demonstrate that the WNT1 protein is 
necessary and sufficient to provide cellular protection during elevated glucose exposure. 
Administration of exogenous Wnt1 protein can significantly prevent apoptotic endothelial cell 
injury during elevated glucose exposure. Interestingly, this protection by WNT1 can be regulated 
by the growth factor and cytokine EPO [110, 111]. Through the Wnt pathway, EPO may offer an 
attractive therapy to maintain proper cellular metabolism and mitochondrial membrane potential 
during conditions of oxidative stress and DM.  
 
EPO can at times enhance tissue function and is closely related to the maintenance of 
mitochondrial membrane potential (Δψm). Loss of Δψm and the subsequent opening of the 
mitochondrial-permeability-transition-pore represent a significant determinant for cell injury and 
the subsequent induction of apoptosis. EPO has the capacity to prevent the depolarisation of the 
mitochondrial membrane that also affects the release of cytochrome c. With the Wnt pathway, 
EPO maintains the expression of Wnt1 during elevated glucose exposure and prevents loss of 
Wnt1 expression that would normally occur in the absence of EPO during elevated glucose. In 
addition, blockade of Wnt1 with a WNT1 antibody can neutralise the protective capacity of EPO, 
illustrating that WNT1 is a critical component in the cyto-protection of EPO during elevated 
glucose exposure [112]. 
Neuronal disease 
The WNT pathway can influence both acute and chronic disease processes of the nervous 
system. For example, experimental models of behaviour suggest that the ability to tolerate stressful 
environments may be associated with the expression of WNT2. Other work suggests that loss of 
WNT signalling may contribute to retinal neurodegeneration as the progressive loss of 
photoreceptors during retinitis pigmentosa has been associated with increased secretion of the 
WNT inhibitory protein SFRP2.  
 
Other reports have also demonstrated that a mutation in the membrane-type SFRP gene may be 
involved in retinal photoreceptor degeneration. In relation to cognitive function, WNT has been 
demonstrated in the brains of individuals affected by neuropsychiatric disorders. In models of 
front-temporal dementia, the WNT pathway can be upregulated early during the onset of the 
disease. It is conceivable that this increased expression of WNT may improve memory function 
similar to the way cognition is improved with agents such as lithium chloride that enhance WNT 
activity, as demonstrated in other work. Genetic analysis also suggests that LRP6 variants of the 
WNT pathway may be associated with late-onset Alzheimer’s disease and that upregulation of the 
WNT pathway with agents such as cannabidiol may provide alternative treatments for Alzheimer’s 
disease. Although it is unclear whether WNT expression has a direct role in the development of 
neuropsychiatric or dementia disorders, the WNT pathway has been tied to several of the 
pathological components of Alzheimer’s disease [113, 114]. The production of β-amyloid (Aβ) 
peptide aggregates composed of 39–42 amino acid peptides and the accumulation of intracellular 
neurofibrillary tangles are considered to be two critical pathological mechanisms that lead to 
Alzheimer’s disease. In Drosophila models of neurodegeneration, WNT can lead to neurofibrillary 
pathology. The proteolytic processing of amyloid precursor protein (APP) during Alzheimer’s 
disease has been closely linked to the WNT pathway through presenilin 1 (PSEN1) and DVL1. 
 
APP cleaves β-amyloid into products that include a 40-residue peptide and a 42-residue peptide 
(Aβ1-42). How-ever, it is Aβ1-42 that is considered to be the β-amyloid product that most directly 
leads to Alzheimer’s disease and apoptotic injury. WNT may regulate APP isoform expression 
[115]. In addition, PSEN1 is required for the processing of APP and has been shown to 
downregulate WNT signalling and interact with β-catenin to promote its turnover. DVL1 also can 
regulate the α-secretase cleavage of APP through protein kinase C/mitogen-activated protein 
kinase dependent pathways, increasing production of soluble APP [116].  
 
Current studies also have examined the ability of WNT to directly reduce β-amyloid toxicity. 
Investigations with lovastatin as an extension of prior clinical work that suggests that a lower 
prevalence of Alzheimer’s disease can occur during statin administration show that this agent can 
reduce β-amyloid production and cellular injury through increased β-catenin activity and the 
inhibition of GSK3B [117]. In addition, the pathways controlled by WNT1 appear to be critical for 
neuronal protection during β-amyloid exposure against genomic DNA degradation, membrane 
Psen exposure and microglial activation. The neuroprotective attributes of WNT1 against β-
amyloid are lost during gene silencing of WNT1 protein expression. More importantly, WNT1 
protection is dependent upon protein kinase B (AKT) activity and the inhibition of GSK3B with 
the cellular translocation of β-catenin to the nucleus. 
Cardiovascular disease 
During the process of wound healing in the heart, changes in components of the WNT-Fzd 
signalling pathway, such as WNT, FZD, DVL1, GSK3B, β-catenin and SFRP can occur. For 
example, during myoblast proliferation and migration following myocardial infarction, elevated 
expression of FZD genes including FZD1, 2, 5, 6, 7, 8and 10has been identified during heart 
remodelling. The overexpression of some FZD genes may be associated with reduction in infarct 
size and the prevention of cardiac rupture to improve cardiac function [118]. It is important to note 
that different members of the WNT family may contribute to distinct events during cardiac injury. 
Both WNT8Aand WNT10Bare upregulated following myocardial infarction while WNT7Bis 
downregulated to undetectable levels during this period [118]. Additional work also has 
demonstrated that β-catenin is translocated from the plasma membrane to the cytoplasm of 
endothelial cells following the expression of DVL during the phase of the neovascularisation after 
myocardial infarction. Furthermore, over-expression of antagonists of the WNT/FZD pathway can 
reverse the benefit of treatments such as ischaemic preconditioning and minimise β-catenin and 
AKT activity.  
 
Furthermore, the expression of another WNT component, DVL1, appears to have a vital role 
during cardiac injury. The expression of DVL1mRNA and cytoplasmic Dvl1 protein is 
significantly enhanced within days in myo-fibroblasts, vascular endothelial cells and smooth 
muscle cells of newly formed and pre-existing blood vessels in the region of a myocardial 
infarction. 
  
In addition, mice without DVL1 demonstrate a benefit from pressure overload cardiac 
hypertrophy that is mediated through AKT and GSK3B [119]. In addition to FZD, DVL1and 
several WNT genes, other members of the WNT signalling cascade also appear to have relevant 
roles during myocardial injury. Other studies illustrate that cardiac rupture following myocardial 
infarction is correlated with decreased levels of β-catenin in cardiomyocytes. The lack of β-catenin 
in the adherence junctions of cardiomyocytes may lead to impaired structural integrity of the heart, 
since β-catenin may play a vital role in a structural adaptor protein linking cadherins to the actin 
cytoskeleton in cell–cell adhesion. Yet, the role of β-catenin during cardiac infarction is not 
entirely clear, since cytosolic β-catenin exists in vascular endothelial cells and smooth muscle cells 
that reside in the area of myocardial infarction [118]. Pathological cardiac hypertrophy also may 
be dependent upon modulation of the WNT pathway. Overexpression of Sfrp1 reduces infarct size 
and improves cardiac function in mice.  
WNT signalling and cancer 
WNT signalling pathway was first causally associated to carcinogenesis when it was found to 
be permanently activated in familial adenomatous polyposis (FAP) [120, 121] and spontaneous 
forms of colon cancer [122, 123]. Chronic activation of WNT signalling in these intestinal tumours 
was the result of inactivating mutations in the APC locus and, to a much lesser extent, in β-catenin 
and AXIN2/conductin genes.  
 
Mutations of APC in colorectal carcinoma (CRC) occur mostly in a mutation cluster region 
that is located approximately in the middle of the coding sequence. The mutations lead to frame 
shifts or stop codons, resulting in the generation of truncated APC proteins that lack several of the 
20-aminoacid repeats that interact with β-catenin and all the SAMP interaction domains for 
AXIN/conductin. It is thought that the resulting disturbance of the architecture of the β-catenin 
destruction complex is responsible for the stabilisation of β-catenin. Moreover, truncated APC also 
lacks several nuclear export sequences (NES) thought to be important for an APC-mediated export 
of β-catenin from the nucleus. In summary, APC mutations lead to accumulation of β-catenin and 
constitutive transcription of WNT target genes in the absence of exogenous WNT factors. It is not 
clear why CRC cells retain the truncated APC versions, i.e., why cancer-generating mutations do 
not completely abolish APC expression. Interestingly, a special form of attenuated FAP, in which 
patients develop much fewer polyps than in the classical FAP, is characterised by mutations that 
generate shorter APC proteins. This indicates that the truncated APC retains some function that is 
required for robust tumorigenesis. β-Catenin is mutated in up to 10% of all sporadic colon 
carcinomas by point mutations or in frame deletions of the serine and threonine residues that are 
phosphorylated by GSK3B. These mutations result in stabilisation of β-catenin and activation of 
WNT signal-ling. β-Catenin and APC mutations are mutually exclusive, possibly reflecting the 
fact that both components act on the same pathway [124]. 
 
Although it appears that mutations of WNT pathway components are sufficient to generate 
constitutive activation of WNT signalling in CRC, recent evidence suggests additional autocrine 
mechanisms involving stimulation of the pathway by secreted WNT proteins. Thus it was shown 
that colorectal cancer cells frequently express WNT, and that the WNT-pathway activity could be 
suppressed by treatment of the cells with SFRP, which interfere with WNT receptor binding. 
Importantly, SFRP genes are subject to inactivation by hypermethylation in the CRC cells, 
indicating an epigenetic mechanism that leads to a boost of the WNT signal [124]. 
 
After these seminal observations, a wide range of hu-man tumours have also been found to 
exhibit an aberrant activation of WNT signalling [125].  
 
Interestingly, in contrast to colon malignancies, aberrant activation of WNT signalling in many 
of these tumours is not the result of mutations in the APC locus. Preferent mutations in β-catenin 
are found in liver cancer (hepato-cellular and hepatoblastoma), endometrial ovarian cancer, 
pilomatricoma skin cancer, prostate cancer, melanoma and Wilm’s tumour [125]. AXIN1 
mutations also occur in liver cancer and medulloblastoma. Other cancers present nuclear β-catenin 
translocation in the absence of mutation in APC, β-cateninor AXIN genes. Recent results indicate 
that this might occur through epigenetic inactivation of natural WNT pathway inhibitors [126]. 
 
Mutations of the AXIN gene and/or its loss of expression have also been found in colorectal 
cancers, oesophageal squamous cell carcinomas, hepatomas, hepatocellular carcinomas, 
medulloblastomas and endometrial ovarian carcinomas. Aberrant WNT signalling may play a role 
in lymphoid neoplasias, such as pre-B-cell leukaemia and myeloid leukaemia [124]. Interestingly, 
the overexpression of DKK1by myeloma cells is associated with the presence of lytic bone lesions 
in patients with multiple myeloma. Thus, deregulation of WNT/β-catenin signalling may be 
involved in the development of many human malignancies. By contrast, WNT5A-mediated non-
canonical pathway may function as a tumour suppressor, as WNT5Ais deleted or has reduced 
expression in haematopoietic tumours [124]. Mice that are hemizygous for WNT5A develop 
myeloid leukaemia and B-cell lymphomas [124]. 
 
Autocrine WNT stimulation has also been observed in other tumour cell types, in particular 
from breast and ovary. WNT signalling might also induce epigenetic changes through histone 
deacetylation. Expression of histone deacetylase 2 (HDAC2) was shown to be suppressed by APC, 
and inhibition of HDAC2 with low-molecular-mass inhibitors reduced intestinal polyp formation 
in the APC mutant Min mice [124]. 
 
The discovery of an aberrant WNT signalling linked to several cancers has fostered interest in 
the development of pharmacological WNT pathway inhibitors. However, despite the effort 
invested in this field, no specific pharmacological inhibitor of WNT signalling has been yet 
discovered [127]. In any case, a number of chemical compounds in use for treating other diseases, 
in particular non-steroidal inflammatory drugs (NSAIDs), and vitamin derivatives can also target 
the WNT signalling pathway [127].  
 
It is generally assumed that inhibition of cyclooxygenase (COX) activity is the most important 
mechanism of action of traditional (aspirin, sulindac and indomethacin) and new-generation 
(celecoxib/Celebrex™, Pfizer; rofecoxib/Vioxx™, Merck) NSAIDs. COX1 and 2 are central 
enzymes in the biosynthesis of prostaglandins [128]. Elevated production of prostaglandins in 
many cancers results in tumour growth, angiogenesis and metastasis [128]. In colon cancer, COX 
activity seems to be directly linked to WNT signalling. Prostaglandin activity can interfere with 
the cytoplasmic β-catenin degradation pathway, promoting the nuclear translocation of this protein 
[129, 130]. 
 
Vitamin A regulates cell growth and differentiation in a number of situations, and is crucial in 
embryonic development, reproduction, vision and immune responses. Vitamin A is metabolically 
converted into retinoids [131]. These compounds exert their biological functions by interaction 
with two families of nuclear receptors, retinoic acid receptor (RAR) and retinoid X receptor 
(RXR) [131]. In the nuclear compartment, both nuclear receptors can directly bind to β-catenin in 
competition with LEF/TCF factors, promoting a severe downregulation of WNT-dependent 
transcriptional activation [132, 133]. Vitamin D is implicated in the regulation of calcium and 
phosphorus levels and is essential in the formation and maintenance of the skeleton. Vitamin D 
derivatives interact with the nuclear vitamin D receptor (VDR) to form a complex that can also 
bind to β-catenin [134, 135]. In addition, active VDR transcription complex can efficiently 
promote the transcription of the E-cadherin (CDH1) gene, contributing to WNT signal inhibition 
by relocalisation of β-catenin to the cell membrane [134]. 
  
Conclusions 
In the last years, an emerging concept suggesting that the origin of most cancers can be 
explained by invoking the existence of putative cancer stem cells has been the matter of intense 
debate [136].The most controversial point with this hypothesis lies in what exactly the term 
“cancer stem cells” is referring to. Now, it is assumed that a cancer stem cell is a any type of 
malignant cell after the acquisition of the basic properties commonly assigned to a normal stem 
cell, that is, the ability to undergo self-renewal and the ability to differentiate into different cell 
types [136]. 
 
This is a functional definition that can be equally ap-plied to different cell types. Thus, a series 
of genetic alterations can provide a normal stem cell with the ability to escape from growth 
restriction controls and to aberrantly expand and differentiate in multiple cells types giving raise to 
a tumour. In the same way, a transit-amplifying cell, i.e., a stem cell that has been committed to 
differentiate, but still retaining part of its differentiation potential, may also undergo genetic 
alterations leading to an unlimited proliferation and differentiation potential. Finally, a normal, 
fully differentiated, mature cell may also undergo a process of genetic and epigenetic alterations 
leading to physiological reversion that ultimately results in the acquisition of stem cell-like 
properties, escape from quiescent state and high proliferation rate. The final outcome in all cases is 
the generation of cancer stem cells. 
 
At present, it is accepted that these cancer stem cells can be essential contributors to the driving 
force that is be-hind the most worrying phenomena observed in malignant tumours, i.e., relapse 
after treatment with chemotherapy or with surgical procedures and generation of metastasis in 
organs distant from the main focus of the tumour. Cancer stem cells are, thus, a subset of cells in 
the tumour with an unlimited capacity to proliferate and differentiate so that they are capable on its 
own to generate a whole tumour population. Current procedures for cancer treatment usually target 
the most abundant, actively proliferating, tumour cell populations, but not the basal cancer stem 
cells, which are in the origin of cancer development, expansion and metastasis. For the eradication 
of cancer, it will be necessary to design new pharmacological and surgical approaches to target 
cancer stem cells. However, to achieve these new approaches it will be necessary to define what a 
normal stem cell is (and by extension, what a cancer stem cell is) through the study of the 
molecular and physiological features that are involved in their peculiar behaviour in normal tissues 
and how their alteration can lead to cancer.  
 
It is increasingly assumed that one the critical steps required to ignite carcinogenesis is the 
alteration of a number of key genes, involved in the signalling pathways that regulate stem cells 
proliferation and differentiation. Wnt signalling is essential during embryo development and in the 
maintenance of adult tissue homeostasis through the regulation of adult stem cell function. 
Therefore, Wnt path-way components are natural candidates as genetic factors that predispose to 
or trigger cancer. For example, it is well established that the alteration of APC is a key step (with 
the development of FAP) leading to colorectal cancer. Equally important, alteration of β-catenin is 
involved in a number of cancer types as liver, endometrial, ovarian, skin, prostate, melanoma and 
Wilm’s tumour. Mutations of AXIN1, also involved in Wnt signalling, are linked to 
medulloblastoma. Finally, aberrant Wnt signalling may also play a key role in lymphoid 
neoplasias, such as pre-B-cell leukaemia or myeloid leukaemia.  
 
Taken together, these data strongly support the idea that Wnt signalling is tightly associated 
with carcinogenesis and that components of this signalling pathway are adequate candidates as 
pharmacological targets. It is also tempting to speculate that aberrant Wnt signalling is involved in 
the generation of cancer stem cells from normal cells. However, it is clear that a better 
understanding of this signalling pathway and its connections with other important pathways is still 
necessary to develop efficient drugs of potential therapeutic application that can specifically target 
cancer stem cells.  
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